Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Temperature excursions

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled.

569 FDA drug recalls with this cause, newest first.

Vaccines, insulin, many injectables and some tablets must stay within a narrow temperature band from factory to pharmacy. A truck without working refrigeration, a freezer failure or a warehouse heatwave is enough: the product looks normal but may have lost potency or formed degradation products. FDA files these under 'CGMP deviations' or 'temperature abuse'; we track them separately because the question to ask - how was my medication stored? - is different from every other cause.

Class II · Moderate risk

ViCTOZA (liraglutide)

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-4060-90 D-0622-2021
Class I · High risk

TRESIBA FlexTouch

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-2550-90 D-0621-2021
Class I · High risk

TRESIBA (insulin degludec injection)

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-2662-90 D-0620-2021
Class I · High risk

TRESIBA FlexTouch

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-2660-90 D-0619-2021
Class II · Moderate risk

Saxenda (liraglutide)

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-2800-90 D-0618-2021
Class II · Moderate risk

OZEMPIC (semaglutide)

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-4132-90 D-0617-2021
Class I · High risk

NovoLog (Insulin aspart)

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-7501-90 D-0616-2021
Class I · High risk

NovoLog FlexPen

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-6339-90 D-0615-2021
Class I · High risk

Levemir FlexTouch

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-6438-90 D-0614-2021
Class I · High risk

Fiasp (insulin aspart injection)

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-3201-90 D-0613-2021
Class I · High risk

Fiasp PenFill

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-3205-91 D-0612-2021
Class I · High risk

Fiasp FlexTouch

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-3204-90 D-0611-2021
Class II · Moderate risk

Brompheniramine Maleate

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Terminated Temperature excursion Cardinal Health Inc. NDC 60432-275-16 D-0596-2021
Class II · Moderate risk

Briviact (brivaracetam)

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Terminated Temperature excursion Cardinal Health Inc. NDC 50474-570-66 D-0591-2021
Class II · Moderate risk

VIMPAT (lacosamide)

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Terminated Temperature excursion Cardinal Health Inc. NDC 0131-2480-35 D-0590-2021
Class II · Moderate risk

VIMPAT (lacosamide)

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Terminated Temperature excursion Cardinal Health Inc. D-0589-2021